Protein measurement for relevant, real-time health information and better treatment decisions

Groundbreaking proteomics technology that provides real-time health information to clinicians for improved outcomes

Risk Stratify
Patients

Personalize therapy. Practice precision medicine to direct the most aggressive interventions to those at highest risk, preventing disease progression, and reducing acute events

Determine disease prognosis

Identify patients with poor disease trajectory to prioritize them for optimized treatment or early screening

Understand
disease drivers

At a glance, and with the same blood sample, review other factors that may be contributing to risk and prognosis for an individual patient

Identify risk in diverse therapeutic areas for population health management

12 SomaSignal tests are currently available for clinical use*

Over 100 more in development

* SomaLogic, Inc. developed the SomaSignal tests and determined their performance characteristics. The tests have neither been cleared nor approved by the US Food and Drug Administration. SomaLogic also offers additional tests for Research Use Only (RUO).

Leading Efforts to monitor health risk in COVID-19 patients

Our 27-protein SomaSignal test could be used to monitor recovery and long-term consequences of COVID-19 infection on the heart

Collaboration with
Massachusetts General Hospital,
Icahn School of Medicine at Mount Sinai, the Institute for Systems Biology,
and others

Funded in part by
Bill & Melinda Gates
Foundation

Providing risk scores that track the
impact of interventions

SomaSignal tests reflect changes in therapy and changes in lifestyle

Secondary cardiovascular risk decreases in a diabetic population as a result of upgraded cardio-protective drug therapy

Ready to start improving patient outcomes with real-time health information?

Contact our team of healthcare implementation experts at info@somalogic.com